Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Some claims (COC nature; smoking/age >35 cardiovascular risk and contraindication; general adverse effects like headache/spotting) are consistent with the provided label excerpts, but multiple mechanistic statements and dosing/pill-pattern details are not supported by the supplied FDA label excerpts and therefore cannot be verified.
Category Scores
Accurate Statements
Tri-Lo-Estarylla is a combined oral contraceptive that contains an estrogen plus a progestin.
Supported only insofar as the provided label excerpt is for a combined oral contraceptive (COC) containing ethinyl estradiol and norgestimate (implied by the sections shown: Estarylla™ norgestimate and ethinyl estradiol).
Combined birth control pills carry risks of blood clots.
Supported by 5.1 stating that the use of COCs increases the risk of VTE.
Risk of blood clots with combined pills is increased with smoking.
Supported by BOXED WARNING stating cigarette smoking increases risk of serious cardiovascular events from COC use and by 5.1 referencing increased thrombotic/cerebrovascular risk particularly in women over 35 who smoke.
Risk of blood clots with combined pills is increased with age over 35.
Supported by BOXED WARNING and 5.1 stating risk increases with age, particularly in women over 35.
Unsupported Statements
Tri-Lo-Estarylla is an oral contraceptive.
Not supported by the provided excerpts; only cardiovascular/thromboembolic warning/contraindication text is included.
Tri-Lo-Estarylla is used for preventing pregnancy.
No indication/efficacy statement is present in the supplied excerpts.
Tri-Lo-Estarylla contains hormones that stop ovulation.
Mechanism-of-action statements (e.g., ovulation suppression) are not present in the supplied excerpts.
Tri-Lo-Estarylla changes cervical mucus to make pregnancy less likely.
Mechanism-of-action statements regarding cervical mucus are not present in the supplied excerpts.
Combined oral contraceptive pills suppress ovulation.
Mechanism-of-action statements are not present in the supplied excerpts.
Combined oral contraceptive pills thicken cervical mucus.
Mechanism-of-action statements are not present in the supplied excerpts.
Combined oral contraceptive pills change the endometrium.
Mechanism-of-action statements are not present in the supplied excerpts.
Tri-Lo-Estarylla is typically taken as a daily regimen.
No dosage/instructions section is included in the supplied excerpts.
Tri-Lo-Estarylla is typically taken in a 21-day active-pill pattern followed by inactive pills or a placebo interval, depending on packaging instructions.
No dosage/pill schedule information is present in the supplied excerpts.
Common side effects of combined oral contraceptive pills can include nausea, breast tenderness, spotting between periods, and headache.
No adverse reaction/side effect list is included in the supplied excerpts.
Contradictions
Low
AI Statement
Tri-Lo-Estarylla is used for preventing pregnancy.
Label Reference
N/A (no contraindication or warning excerpt contradicts an indication statement, but the label excerpt provided does not support the claim).
Important Omissions
Accurate product naming/label alignment: the label excerpts provided are for Estarylla™ (norgestimate and ethinyl estradiol), not Tri-Lo-Estarylla.
Importance:
Moderate
For safety-critical dosing/administration claims (daily regimen; 21 active days with placebo/inactive interval), the supplied excerpts do not include the required dosing schedule details; these omissions prevent verification against label.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Mechanism and dosing/schedule claims are not supported by the provided label excerpts, and therefore could be inaccurate relative to the specific product. However, cardiovascular risk and contraindication-related claims align with the provided boxed warning/5.1 excerpt.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Multiple claims (indication, mechanism of action, and dosing/pill pattern, and common side effects) are not supported by the provided FDA label excerpts, and the excerpted label appears to be for Estarylla™ rather than Tri-Lo-Estarylla.
Suggested Improvement
Restrict statements to what is present in the provided label excerpts: boxed warning/contraindication regarding smoking and age >35 and the general statement that COCs increase VTE risk. Provide the specific label sections (indications, dosage/administration, adverse reactions) for Tri-Lo-Estarylla/Estarylla to verify remaining claims.